Adamik B, Zimecki M, Właszczyk A, Berezowicz P, Kübler A
Department of Anesthesiology and Intensive Therapy, University Medical School, Wrocław, Poland.
Arch Immunol Ther Exp (Warsz). 1998;46(3):169-76.
The aim of the study was to investigate whether lactoferrin can improve the immune competence of cells from patients with systemic inflammatory response syndrome (SIRS). We studied the effect of lactoferrin (LF) on the proliferative response of peripheral blood mononuclear cells (PBMC) to lipopolisaccharide (LPS) in vitro and its influence on production of 2 proinflammatory cytokines: interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). Three groups of patients: septic survivors, septic nonsurvivors and multiple trauma patients, were investigated. Blood samples were taken upon admission to intensive care unit and after 2, 3 and 5 days. The proliferative response of PBMC in vitro was tested using 3-day culture with LPS. Cell proliferation/death was measured using MTT colorimetric method. The spontaneous and LPS-induced activity of TNF-alpha and IL-6 were measured with bioassays using indicator cell lines WEHI-164.13 and 7TD1, respectively. We demonstrated that LF inhibited the proliferative response, both spontaneous and LPS-induced, in all groups of patients. Lactoferrin alone was a good inducer of IL-6 and TNF-alpha production by monoclear cells in vitro. Addition of LF to the cultures of LPS-activated mononuclear cells stimulated IL-6 production, most markedly in the group of septic survivor patients (mean 1479, 1452, 1728, 1980 pg/ml on day 1, 2, 3 and 6 respectively). Lactoferrin also upregulated TNF-alpha production. That effect was very significant in the septic survivor patients (mean 7407, 6739, 7498 and 8509 pg/ml on day 1, 2, 3 and 5 respectively) and less pronounced in the group of trauma patients. We conclude that lactoferrin exhibited regulatory actions on the altered reactivity of PBMC from patients with sepsis and multiple injury. Lactoferrin is a good inducer of IL-6 and TNF-alpha production. However, in most cases of septic nonsurvivors LF could not abolish low reactivity of cells with regard to cytokine production.
本研究的目的是调查乳铁蛋白是否能提高全身炎症反应综合征(SIRS)患者细胞的免疫能力。我们在体外研究了乳铁蛋白(LF)对人外周血单个核细胞(PBMC)对脂多糖(LPS)增殖反应的影响及其对两种促炎细胞因子:白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)产生的影响。研究了三组患者:脓毒症幸存者、脓毒症非幸存者和多发伤患者。在入住重症监护病房时以及2、3和5天后采集血样。PBMC在体外的增殖反应通过与LPS进行3天培养来检测。使用MTT比色法测量细胞增殖/死亡。分别使用指示细胞系WEHI-164.13和7TD1的生物测定法测量TNF-α和IL-6的自发活性和LPS诱导的活性。我们证明,LF抑制了所有患者组中自发的和LPS诱导的增殖反应。单独的乳铁蛋白是体外单核细胞产生IL-6和TNF-α的良好诱导剂。将LF添加到LPS激活的单核细胞培养物中可刺激IL-6的产生,在脓毒症幸存者组中最为明显(第1、2、3和6天分别为平均1479、1452、1728、1980 pg/ml)。乳铁蛋白还上调了TNF-α的产生。该作用在脓毒症幸存者患者中非常显著(第1、2、3和5天分别为平均7407、6739、7498和8509 pg/ml),在创伤患者组中则不太明显。我们得出结论,乳铁蛋白对脓毒症和多发伤患者PBMC改变的反应性具有调节作用。乳铁蛋白是IL-6和TNF-α产生的良好诱导剂。然而,在大多数脓毒症非幸存者病例中,LF无法消除细胞在细胞因子产生方面的低反应性。